JP2016520077A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520077A5 JP2016520077A5 JP2016513459A JP2016513459A JP2016520077A5 JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5 JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016513459 A JP2016513459 A JP 2016513459A JP 2016520077 A5 JP2016520077 A5 JP 2016520077A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hcv
- hcv genotype
- genotype
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000711549 Hepacivirus C Species 0.000 claims description 320
- 229920001184 polypeptide Polymers 0.000 claims description 294
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 294
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 294
- 239000000203 mixture Substances 0.000 claims description 103
- 108700008783 Hepatitis C virus E1 Proteins 0.000 claims description 26
- 230000001939 inductive effect Effects 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 150000001508 asparagines Chemical class 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 229940037003 alum Drugs 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823712P | 2013-05-15 | 2013-05-15 | |
| US61/823,712 | 2013-05-15 | ||
| US201361887229P | 2013-10-04 | 2013-10-04 | |
| US61/887,229 | 2013-10-04 | ||
| PCT/IB2014/001972 WO2015132619A1 (en) | 2013-05-15 | 2014-05-15 | E1e2 hcv vaccines and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087976A Division JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520077A JP2016520077A (ja) | 2016-07-11 |
| JP2016520077A5 true JP2016520077A5 (cg-RX-API-DMAC7.html) | 2017-06-22 |
Family
ID=54054625
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210145963A9 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2996718B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2016520077A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112999344A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014385320B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2909586C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2015003333A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015132619A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016336150B2 (en) * | 2015-10-08 | 2023-08-10 | The Governors Of The University Of Alberta | Hepatitis C virus E1/E2 heterodimers and methods of producing same |
| AU2017332854B2 (en) * | 2016-09-21 | 2024-11-14 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
| US10881726B2 (en) | 2016-10-11 | 2021-01-05 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
| CA3093314A1 (en) | 2018-03-16 | 2019-09-19 | The Governors Of The University Of Alberta | Hepatitis c virus peptide compositions and methods of use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1996004301A2 (en) | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| EP1039935A4 (en) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
| CA2288374A1 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| CA2293489C (en) | 1997-06-06 | 2009-09-29 | The Regents Of The University Of California | Inhibitors of dna immunostimulatory sequence activity |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| TR200002930T2 (tr) | 1998-04-09 | 2000-12-21 | Smithkline Beecham Biologicals S.A. | Kolaylaştırıcı kompozisyonlar |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| US7357936B1 (en) | 1998-10-16 | 2008-04-15 | Smithkline Beecham Biologicals, Sa | Adjuvant systems and vaccines |
| EP1162999B1 (en) | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| AU766635B2 (en) | 1999-09-24 | 2003-10-23 | Smithkline Beecham Biologicals (Sa) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| JP4370161B2 (ja) * | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｈｃｖｅ１ｅ２ワクチン組成物 |
| US7348011B2 (en) * | 2005-06-10 | 2008-03-25 | Sudershan Biotech Ltd. | Hepatitis C virus vaccine |
| WO2007041432A2 (en) * | 2005-09-30 | 2007-04-12 | Novartis Vaccines And Diagnostics, Inc. | Cross-neutralization of hcv with recombinant proteins |
| WO2009061739A1 (en) * | 2007-11-06 | 2009-05-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralization of hcv |
| WO2014060851A2 (en) * | 2012-10-05 | 2014-04-24 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
-
2014
- 2014-05-15 WO PCT/IB2014/001972 patent/WO2015132619A1/en not_active Ceased
- 2014-05-15 CA CA2909586A patent/CA2909586C/en active Active
- 2014-05-15 JP JP2016513459A patent/JP2016520077A/ja not_active Withdrawn
- 2014-05-15 US US14/783,699 patent/US20210145963A9/en not_active Abandoned
- 2014-05-15 AU AU2014385320A patent/AU2014385320B2/en active Active
- 2014-05-15 CN CN202110252076.3A patent/CN112999344A/zh active Pending
- 2014-05-15 EP EP14884476.4A patent/EP2996718B1/en active Active
- 2014-05-15 EP EP19215826.9A patent/EP3689375A1/en not_active Withdrawn
- 2014-05-15 CN CN201480027001.3A patent/CN105263517B/zh active Active
-
2015
- 2015-11-13 CL CL2015003333A patent/CL2015003333A1/es unknown
-
2019
- 2019-05-08 JP JP2019087976A patent/JP2019142962A/ja not_active Withdrawn
-
2020
- 2020-01-10 AU AU2020200216A patent/AU2020200216A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021001926A patent/JP2021059596A/ja active Pending
-
2022
- 2022-02-04 AU AU2022200747A patent/AU2022200747A1/en not_active Abandoned
- 2022-03-23 US US17/702,231 patent/US20230098265A1/en not_active Abandoned
- 2022-08-31 JP JP2022137454A patent/JP2022172244A/ja active Pending
-
2023
- 2023-11-27 US US18/520,057 patent/US20240316186A1/en active Pending
-
2024
- 2024-08-07 JP JP2024130501A patent/JP2024156917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Filippelli et al. | Hepatitis B vaccine by intradermal route in non responder patients: an update | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| JP2017524682A5 (cg-RX-API-DMAC7.html) | ||
| Ross et al. | Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice | |
| HRP20201953T1 (hr) | Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b | |
| JP2016531144A5 (cg-RX-API-DMAC7.html) | ||
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2018523668A5 (cg-RX-API-DMAC7.html) | ||
| RU2020117033A (ru) | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение | |
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| JP2012526839A5 (cg-RX-API-DMAC7.html) | ||
| Romeli et al. | Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials | |
| JP2016508999A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520077A5 (cg-RX-API-DMAC7.html) | ||
| Hasegawa et al. | Mucosal immunization and adjuvants | |
| FI3166615T3 (fi) | Kelatoituja fosforotioaattinukleiinihappopolymeerejä käytettäväksi yhdistelmänä HBV-polymeraasin inhibiittorin kanssa hepatiitti B- ja hepatiitti D -virusinfektioiden hoitamiseksi | |
| MX351380B (es) | Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino. | |
| NZ618158A (en) | Compositions and methods for administration of vaccines against dengue virus | |
| JP2017526689A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512194A5 (cg-RX-API-DMAC7.html) | ||
| Bhandari et al. | Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic | |
| Kim et al. | Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection | |
| JP2019500379A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510064A5 (cg-RX-API-DMAC7.html) |